WO2020022975A3 - New pharmaceutical compositions in the treatment of copd - Google Patents

New pharmaceutical compositions in the treatment of copd Download PDF

Info

Publication number
WO2020022975A3
WO2020022975A3 PCT/TR2018/000134 TR2018000134W WO2020022975A3 WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3 TR 2018000134 W TR2018000134 W TR 2018000134W WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical compositions
copd
new pharmaceutical
new
Prior art date
Application number
PCT/TR2018/000134
Other languages
French (fr)
Other versions
WO2020022975A2 (en
Inventor
Mahmut Bi̇lgi̇ç
Original Assignee
Neutec Ar-Ge Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Ar-Ge Sanayi Ve Ticaret Anonim Sirketi filed Critical Neutec Ar-Ge Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020022975A2 publication Critical patent/WO2020022975A2/en
Publication of WO2020022975A3 publication Critical patent/WO2020022975A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising N-Acetycysteine and mannitol for use in the treatment of COPD attacks.
PCT/TR2018/000134 2017-12-29 2018-12-28 New pharmaceutical compositions in the treatment of copd WO2020022975A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/022950 2017-12-29
TR2017/22950A TR201722950A2 (en) 2017-12-29 2017-12-29 New pharmaceutical compositions in the treatment of COPD.

Publications (2)

Publication Number Publication Date
WO2020022975A2 WO2020022975A2 (en) 2020-01-30
WO2020022975A3 true WO2020022975A3 (en) 2020-02-27

Family

ID=67901361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/000134 WO2020022975A2 (en) 2017-12-29 2018-12-28 New pharmaceutical compositions in the treatment of copd

Country Status (2)

Country Link
TR (1) TR201722950A2 (en)
WO (1) WO2020022975A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116098886B (en) * 2023-01-12 2024-04-26 澳门科技大学 Pharmaceutical composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
US20070065373A1 (en) * 2003-09-15 2007-03-22 Vectura Ltd. Mucoactive agents for treating a pulmonary disease
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065373A1 (en) * 2003-09-15 2007-03-22 Vectura Ltd. Mucoactive agents for treating a pulmonary disease
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ODZIOMEK, M. ET AL.: "Conception, preparation and properties of functional carrier particles for pulmonary drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 433, no. 1-2, 5 January 2012 (2012-01-05), pages 51 - 59, XP028493598 *
SNIJDERS, D. ET AL.: "Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 26, no. 2, pages 529 - 534, XP055687438 *
WEINBROUM, A. A. ET AL.: "Concomitant administration of mannitol and N-acetylcysteine for the prevention of lung reperfusion injury", JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, vol. 60, no. 6, 2006, pages 1290 - 1296, XP055687440 *

Also Published As

Publication number Publication date
WO2020022975A2 (en) 2020-01-30
TR201722950A2 (en) 2019-07-22

Similar Documents

Publication Publication Date Title
MX2015011898A (en) Pyrazolo compounds and uses thereof.
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
IL271807A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2015120062A3 (en) Therapeutic compounds and compositions
IL261444A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2016142708A3 (en) Pharmaceutical composition
WO2018226992A8 (en) Tau aggregation inhibitors
EP3651801A4 (en) Compositions and methods for the treatment of fungal infections
BR112015013675A2 (en) compositions comprising vortioxetine and donepezil
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
EA201691792A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
EP3600277A4 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd
WO2016069542A3 (en) Lactone compounds and methods of making and using same
PH12019500180A1 (en) Compositions for the treatment of pulmonary fibrosis
HK1257448A1 (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
EP3265108A4 (en) Peptides and compositions comprising same and uses thereof in the treatment of diseases
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18927968

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18927968

Country of ref document: EP

Kind code of ref document: A2